Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 17/20 | 0.78 |
| ▸ | CNR1 | P21554 | 9/20 | 0.78 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892225 | 0.90 | CNR2 (0.82) | CNR2CNR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL9892273 | 0.89 | CNR2 (0.62) | CNR2CNR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL9892040 | 0.88 | CNR2 (1.00) | CNR2CNR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL9892227 | 0.85 | CNR2 (0.61) | CNR2CNR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL9892196 | 0.81 | CNR2 (0.82) | CNR2CNR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL9892331 | 0.80 | CNR2 (0.64) | CNR2CNR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL9892270 | 0.78 | CNR2 (0.76) | CNR2CNR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL9892804 | 0.78 | CNR2 (0.62) | CNR2CNR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL2580450 | 0.77 | CNR2 (0.55) | CNR2CNR1CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL9892833 | 0.76 | CNR2 (0.60) | CNR2CNR1CYP2C8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885CYP2C8 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.